| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? | Clin Cancer Res | 2009 | 1.04 |
| 2 | The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. | Mol Cancer Ther | 2011 | 0.94 |
| 3 | Developmental lineage priming in Dictyostelium by heterogeneous Ras activation. | Elife | 2013 | 0.81 |